FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
Executive Summary
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
You may also be interested in...
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition
Generic Firms Object To Policy Behind Residual Solvents Deficiency Letters
FDA's Office of Generic Drugs has interpreted a new pharmacopoeial standard for residual solvents in an unexpectedly rigorous manner, rejecting dozens of applications and raising the ire of generic drug manufacturers